Press Release NKI/CRC/Surfix

Surfix Diagnostics, the Netherlands Cancer Institute and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Amsterdam and Wageningen, Netherlands, July 10, 2024: Today, Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announce a collaboration aimed at enhancing colorectal cancer (CRC) screening methods. This project is set to leverage Surfix Diagnostics' advanced photonic diagnostic platform and novel biomarkers targeting molecularly-defined high risk precursor lesions and cancer discovered by NKI. This project is, supported by a PPP grant from the TKI-program Life Sciences & Health of Health-Holland, marking a significant step forward in non-invasive colorectal cancer early detection. 

The full text of the press release can be found here: Life Science Newswire